Johnson & Johnson rises as healthcare peers climb after device launch and sector strength

What happened

Johnson & Johnson (JNJ) rose 2.2% on October 20, 2026, after the healthcare sector rallied and the company highlighted a new coronary intravascular lithotripsy device. The stock mainly moved with its sector median, though Johnson & Johnson recently launched its Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S., according to Business Wire and GuruFocus.

How big was the move

The stock closed at $259.36, a rise of 2.2% on a day when the S&P 500 rose 0.3% and the healthcare sector median rose 3.0%. Trading volume was 1.0 times its 20-day average and the session represented 1.5 times a typical daily move for this stock. Over the last five sessions the stock rose 4.3% while the S&P 500 over five sessions fell 1.2%. Compared with its sector, the session was 0.8 percentage points worse than the sector median.

The technical picture

The stock was 0.3% below its 20-day moving average and 2.2% below its 50-day moving average, while it sat 6.0% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has been above the 200-day average for 319 consecutive trading days. The Relative Strength Index (14 days) was 49, in a neutral range between 30 and 70, and the shares were 7.7% below the 52-week high. Over one month the stock fell 3.8%, over three months it rose 1.5%, and over one year it rose 34.2%, which is 18.5 percentage points ahead of the S&P 500. Volatility was 23% annualized over 60 days, higher than 91% of its own readings over five years.

Fundamentals and valuation

For the four quarters through September 30, 2026, Johnson & Johnson reported revenue of $99.33 billion, which grew 7.8% from a year earlier and compared with growth of 8.1% one quarter earlier. Diluted earnings per share were $6.60, with earnings per share growth from a year earlier down 36.3%. Gross margin was 68.8% versus 68.1% a year earlier, and operating margin was 25.7% versus 26.1% a year earlier. Return on invested capital was 14.7% and share count over one year increased by 0.8%.

Valuation metrics show the stock at 39.3 times trailing earnings and 23.2 times expected forward earnings. The price to trailing earnings is higher than 95% of its own readings over the past five years, with a five-year median of 24.0 times earnings. PromtFinance scores rank the company 54 for Value (Neutral), 32 for Growth (Weak), 99 for Quality (Exceptional), 70 for Momentum (Positive), 23 for Revisions (Very weak), and 100 for Stability (Exceptional).

Earnings and analyst expectations

Johnson & Johnson last reported on October 13, 2026, with earnings per share of $2.59 against $2.52 expected, 2.8% above estimates. That marked three consecutive quarters beating estimates and an average surprise over the last four reports of 1.3% above estimates. Typical two-day reactions after recent reports were a fall of 0.5%. The next report is scheduled for January 20, 2027. The consensus price target among 40 analysts was $284.33, 9.6% above the closing price, and 52% of analysts rated the stock Buy or Strong Buy with a consensus rating of Buy.

What to watch

• January 20, 2027: next scheduled earnings report
• October 13, 2026: last report EPS $2.59, 2.8% above estimates
• Distance from 52-week high: 7.7% below the 52-week high
• Price to trailing earnings: 39.3 times trailing earnings
• Shockwave C2 Aero Fly Coronary IVL Catheter launch in the U.S., reported by Business Wire and GuruFocus